The present invention relates to a pharmaceutical composition (nanosuspension) for long-acting injectable (LAI) drug for long-term supportive therapy of HIV/AIDS.

A pharmaceutical nanosuspension to be used as an injectable drug for long-term supportive therapy of HIV infection comprising a composition containing, as an active ingredient, a compound of general formula 1 in a crystalline or polycrystalline form

##STR00001## wherein is C.sub.2H.sub.5CON.sup.Na.sup.+, NH.sub.2.

The present disclosure pertains to combinations comprising immuno-oncology agents with belinostat or a pharmaceutically acceptable salt thereof, for use in treating various forms of cancer and in increasing anti-tumor activity and anti-tumor immune response in a patient in need thereof.

The present disclosure pertains to combinations comprising immuno-oncology agents with belinostat or a pharmaceutically acceptable salt thereof, for use in treating various forms of cancer and in increasing anti-tumor activity and anti-tumor immune response in a patient in need thereof.

Provided is a compound having 4 integrin inhibitory action. The compound is a sulfonamide derivative represented by the following formula (I), or pharmaceutically acceptable salt thereof: ##STR00001##
where R.sub.1 to R.sub.5, e to h, D, and B represent those as described in the specification.

The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using .sub.1-adrenergic receptor (.sub.1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.

The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using .sub.1-adrenergic receptor (.sub.1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.

The invention relates to the use of selective agonists of beta-3 adrenergic receptors for the treatment and/or prevention of pulmonary hypertension.

The invention relates to the use of selective agonists of beta-3 adrenergic receptors for the treatment and/or prevention of pulmonary hypertension.

The invention relates to the use of selective agonists of beta-3 adrenergic receptors for the treatment and/or prevention of pulmonary hypertension.

The present disclosure relates to compounds having the Formula (Formula (I)) which are inhibitors of STAT5. ##STR00001##